Date: November 4, 2022

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization, Part 2 – Immunization of Special Populations & Part 4 – Biological Products

Part 2 – Immunization of Special Populations

Select Populations

Individuals new to Canada

- Content has been added for the review of immunization records which include fractional doses of inactivated polio vaccine provided outside of Canada.
- Embedded hyperlinks have been updated throughout the document.

Please remove page numbers: 1-3 dated March 2017
Please add new page numbers: 1-3 dated November 2022

Part 4 – Biological Products

COVID-19 Vaccines

The following COVID-19 vaccine product pages have been updated to indicate the following:

Fall booster dose recommendations have been clarified to indicate that a minimum interval of at least 3 months between completion of the primary series or a previous booster dose and the fall booster may be considered in the context of heightened epidemiologic risk or for operational considerations.

COVID-19 Vaccine Comirnaty® (Pfizer-BioNTech) Adult/Adolescent (Gray Vial Cap)

Please remove page numbers: 1-5 dated October 11, 2022
Please add new page numbers: 1-6 dated November 4, 2022
COVID-19 Vaccine Comirnaty® (Pfizer-BioNTech) Adult/Adolescent (Purple Vial Cap)

Please remove page numbers: 1-5 dated October 11, 2022
Please add new page numbers: 1-6 dated November 4, 2022

COVID-19 Vaccine COMIRNATY® (Pfizer-BioNTech) 5-11 years of age (Orange Vial Cap)

Please remove page numbers: 1-5 dated October 28, 2022
Please add new page numbers: 1-5 dated November 4, 2022

COVID-19 Vaccine COMIRNATY® Bivalent (Pfizer-BioNTech)

Please remove page numbers: 1-4 dated October 11, 2022
Please add new page numbers: 1-4 dated November 4, 2022

COVID-19 Vaccine SPIKEVAX™ (Moderna) 6 Years of Age and Older (Red Vial Cap)

Please remove page numbers: 1-5 dated October 11, 2022
Please add new page numbers: 1-5 dated November 4, 2022

COVID-19 mRNA Vaccine Spikevax™ Bivalent (Moderna)

Please remove page numbers: 1-4 dated October 11, 2022
Please add new page numbers: 1-4 dated November 4, 2022

COVID-19 Vaccine VAXZEVRIA™ (AstraZeneca)

Please remove page numbers: 1-4 dated September 14, 2022
Please add new page numbers: 1-4 dated November 4, 2022

COVID-19 Vaccine (Ad26.COV2.S [recombinant]) JCOVDEN™ (Janssen Inc.)

Please remove page numbers: 1-4 dated September 8, 2022
Please add new page numbers: 1-4 dated November 4, 2022
COVID-19 Vaccine NUVAXOVID™ (Novavax)

Please remove page numbers: 1-3 dated September 14, 2022
Please add new page numbers: 1-3 dated November 4, 2022

Diphtheria & tetanus-containing Vaccines

Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Polio-Haemophilus Influenzae Type b Adsorbed (DTaP-HB-IPV-Hib)

- Administration: Content has been revised to include reconstitution.
- Product components: updated based on the most recent product monograph.
- Special Considerations: content has been added for consideration of those who have a history of receiving fractional doses of inactivated polio vaccine.

Please remove page numbers: 1-2 dated March 2017
Please add new page numbers: 1-2 dated November 2022

Diphtheria-Tetanus-Acellular Pertussis-Polio-Haemophilus Influenzae Type b Adsorbed (DTaP-IPV-Hib)

Special Considerations: content has been added for consideration of those who have a history of receiving fractional doses of inactivated polio vaccine.

Please remove page numbers: 1-2 dated October 2017
Please add new page numbers: 1-3 dated November 2022

Tetanus-Diphtheria-Acellular Pertussis Adsorbed-Inactivated Polio (Tdap-IPV)

- Product Components: updated based on the most recent product monographs.
- Special Considerations: content has been added for consideration of those who have a history of receiving fractional doses of inactivated polio vaccine.

Please remove page numbers: 1-3 dated October 2017
Please add new page numbers: 1-3 dated November 2022
**Polio Vaccine**

**Polio Vaccine (Inactivated)**

Doses and Schedule and Special Considerations: content has been added to indicate a history of two fractional doses of inactivated polio vaccine can be considered equivalent to a single IPV dose provided the first dose was given at a minimum age of 6 weeks with a minimum interval of 4 weeks between doses.

**Please remove page numbers:** 1-2 dated March 2017  
**Please add new page numbers:** 1-2 dated November 2022

**Monkeypox Vaccine**

**Smallpox and Monkeypox Vaccine (Live attenuated, non-replicating): IMVAMUNE®**

- Doses and Schedule: an additional footnote has been added to indicate the standard subcutaneous dose regimen is preferred, and the alternate subcutaneous and intradermal dose regimen may be considered when dose-sparing strategies are required.
- Administration: thawing time has been revised to align with Health Canada recommendations.
- Special Considerations: content has been updated to include that the administration of IMVAMUNE® for pre-exposure prophylaxis should not be delayed in an individual who has recently received another vaccine.

**Please remove page numbers:** 1-4 dated October 11, 2022  
**Please add new page numbers:** 1-4 dated November 4, 2022

**The following documents have been updated:**

- [Guidance on the Management of Inadvertent COVID-19 Vaccine Errors](#)
- [World Health Organization (WHO) Emergency Use Authorization (EUA) Qualified COVID-19 Vaccines](#)
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

cc:
Provincial Health Officer
Dr. Bonnie Henry

BC Ministry of Health,
Population & Public Health Division:

Brian Sagar
Senior Director Communicable Disease,
Population and Public Health Division

Bernard Achampong
Executive Director,
Public Health, Planning and Prevention,
Population and Public Health Division